Why one operation instead of two

If you have been quoted for autologous chondrocyte implantation (ACI) or its matrix variant MACI, you will already know the timetable: a first operation to harvest a small cartilage biopsy, a wait of several weeks while cells are cultured in an external specialist laboratory, and then a second operation — under a separate anaesthetic — to implant the expanded cells. From first consultation to the end of that second surgery, the treatment calendar typically spans three to six months.

STACi (Scaffold-based Tissue-engineered Autologous Chondrocyte Implantation) collapses that two-stage pathway into a single operative session lasting approximately two and a half to four hours. The central difference is not merely logistical convenience: rather than shipping harvested cells to an off-site laboratory, the laboratory is physically brought into the operating theatre on the day of surgery. A dedicated lab team processes the biopsy immediately — enzymatically freeing the chondrocytes from the harvested tissue without altering their character — while the surgical team simultaneously aspirates bone marrow from the joint area to isolate mesenchymal stem cells. The prepared cell construct is seeded onto a collagen scaffold and implanted within the same sitting.

Two further distinctions matter to patients comparing options. First, STACi does not require a periosteum graft — the strip of tissue harvested from the shin to cover the repair site in first-generation ACI — because the three-dimensional scaffold itself provides structural containment. Second, a single anaesthetic carries lower cumulative risk than two separate general anaesthetics, and removes the clinical uncertainty that accompanies any inter-stage waiting period, including the risk that the defect continues to enlarge before implantation takes place.

STACi is a next-generation variant of an established cell-based repair pathway, not an unrelated experimental technique. It is currently available at one centre in the UK.

What happens during the STACi procedure

The session begins with an arthroscopic biopsy. A small fragment of healthy cartilage is taken from a non-weight-bearing zone of the joint — an area chosen specifically because removing tissue there does not compromise the patient's function. That biopsy is passed immediately to a dedicated lab team working alongside the surgical team in the same theatre, rather than being packaged and dispatched to an external facility.

The lab team cuts the fragment into small pieces and applies a digestive enzyme to free the chondrocytes from the surrounding matrix — a process sometimes described as a 'jailbreak' for the cells. The critical point is what the enzyme does not do: it does not manipulate or alter the cells' character. Chondrocytes harvested and processed this way retain the native phenotype they had inside the joint. When cells are instead expanded over several weeks in an external laboratory — as in traditional ACI and MACI — that extended culture period can degrade their biological identity. Avoiding it is one of the core biological arguments for single-session processing.

While the lab team works on the biopsy, bone marrow is aspirated from the surgical area. The aspirate is concentrated, the mesenchymal stem cells (MSCs) are isolated and washed, and a sample is verified and counted under a microscope before anything is seeded.

Meanwhile, the defect is measured intraoperatively and a precisely shaped template is made for the collagen scaffold — a three-dimensional, sponge-like structure that supports cell growth in both depth and surface area. The chondrocytes and concentrated MSCs are mixed and seeded onto this scaffold. The seeded construct is then implanted into the prepared defect site and secured.

The procedure, developed by Professor Paul Lee at London Cartilage Clinic, is conducted by a combined surgical and laboratory team; both are present and working in coordination throughout the same operative sitting, which typically lasts two and a half to four hours.

Which patients are suitable for STACi

Candidacy for STACi rests on two filters: the nature of the cartilage damage and the patient's biological profile.

The right type of damage

STACi addresses focal cartilage defects — discrete lesions where the surrounding cartilage and broader joint architecture remain substantially intact. No cartilage regeneration technique, STACi included, can restore a joint whose articular surface has been lost broadly: diffuse or whole-joint arthritis falls outside the scope of this procedure, and a candid assessment will say so clearly.

Within the focal-defect bracket, the scaffold architecture meaningfully widens eligibility compared with classical ACI. Defects that were historically considered too large or too geometrically complex for first-generation cell implantation — where reliable coverage of an irregular surface was difficult — can be addressed with STACi because the three-dimensional collagen scaffold is templated intraoperatively to fit the specific lesion. Multiple sites within the same joint, such as medial condyle and patello-femoral damage, can be treated in the same operative session. And where traditional ACI was largely confined to the knee, STACi is applicable to the hip, shoulder, ankle, and other joints.

Patients who have previously undergone microfracture without a satisfactory outcome may also be considered. This matters clinically: evidence from the ACI lineage indicates that prior marrow-stimulation procedures are associated with higher failure rates in subsequent cell-based repair, yet a significant proportion of patients seeking further treatment will have had microfracture as their first intervention. Suitability in this group requires careful individual evaluation rather than automatic exclusion.

The right biological profile

STACi is primarily indicated for biologically younger patients — broadly under 40, and potentially up to around 45, where biological rather than chronological age is the meaningful measure. Cartilage regeneration depends on cellular vitality and tissue-remodelling capacity, both of which diminish with age and with the degree of surrounding joint wear.

The clearest candidate is someone under 45 with a focal defect of meaningful size or complexity, in good general joint health around the lesion, who wants to address their cartilage damage in a single operative episode. Confirming whether that profile applies to a specific case is the role of an individual assessment with Professor Paul Lee at London Cartilage Clinic.

What the evidence currently shows

No large-scale randomised controlled trial data exist specifically for STACi as of mid-2026. That gap should be stated at the outset, not tucked into a footnote: anyone assessing this procedure — patient or referring clinician — deserves to know it is a next-generation variant still in early clinical adoption, not a technique with decades of head-to-head trial evidence behind it.

The most legitimate proxy is the established ACI evidence base. Because STACi preserves the core cell biology of autologous chondrocyte implantation — the same chondrocyte-centred repair logic, now deployed in a single session with MSC augmentation and a three-dimensional scaffold — ACI outcome data from longer-running cohort series offer a reasonable benchmark for what the regenerative mechanism can achieve.

In that parent body of evidence, published series report successful outcomes in approximately 82–92% of patients. Lysholm knee scores — a validated patient-reported measure of function and symptoms — improve by an average of 24.9 points. Return to sport is recorded in 70–79% of patients across ACI cohorts, and roughly 75% of outcomes are reported as durable at ten or more years' follow-up. One biological advantage that carries across from ACI to STACi is the quality of tissue produced: the regeneration process favours hyaline-like cartilage rather than the fibrocartilage laid down after marrow-stimulation procedures such as microfracture, which tends to degrade mechanically within two to three years.

Emerging evidence suggests that adding platelet-rich plasma (PRP) at the time of STACi may further improve the quality of cartilage regeneration, and this is cited by the procedure's developer as the next likely enhancement to the technique. It remains an area of active interest rather than an established part of the protocol, and large-scale confirmatory data are still awaited.

The honest position is this: STACi's clinical rationale is well-grounded in established cell biology, but its own outcomes dataset is still maturing. That is the expected position for a next-generation procedure in early adoption — and the ACI lineage, with its multi-decade follow-up, is the evidence base patients and clinicians can reasonably draw on until STACi-specific trial data emerge.

Recovery timeline after STACi

Planning around surgery means knowing, in practical terms, when you can drive, when you can return to a desk job, and when you can think about sport again. Recovery after STACi follows the graduated timeline established for ACI — a useful guide given the procedural kinship, though it should be read as an approximate framework rather than a fixed schedule.

For the first six to eight weeks, the priority is protecting the implant while the scaffold begins to integrate. Walking aids support a gradual increase in weight-bearing over this period; full unprotected weight-bearing is typically reached by the end of that window. Rehabilitation from this point is not optional: the quality and pace of recovery are directly tied to structured physiotherapy, and the programme will be guided by how the joint responds.

Light, low-impact activities — gentle cycling, swimming, walking on even ground — are usually possible from a few months post-surgery as soft-tissue healing consolidates. The restriction on higher-demand movement is not arbitrary: the regenerating tissue needs mechanical loading to mature, but premature impact can disrupt the process before the scaffold has remodelled sufficiently.

Return to sport and high-impact activity is typically considered from nine to twelve months. The underlying reason for that threshold is biological: full cartilage maturation continues to approximately eighteen months after surgery, meaning the tissue reaching sporting loads before that point is still developing its structural properties. Defect size, the joint involved, and consistent adherence to rehabilitation all influence where within these ranges an individual patient lands — which is why recovery planning is best discussed in detail at the post-operative review rather than set in advance.

Cost, insurance, and how to access STACi in the UK

The all-inclusive price for STACi at London Cartilage Clinic is £28,000, covering theatre time, the collagen scaffold, biological processing, the consultant anaesthetist, and a structured twelve-month follow-up programme. There are no staged billing surprises — the single operation means a single consolidated cost.

UK private health insurers do not routinely cover STACi as of mid-2026. Patients with existing cover should check with their insurer directly, but should not assume reimbursement without confirmation in advance.

For context, NHS ACI under NICE Technology Appraisal TA477 carries a benchmark cost of approximately £16,000 per patient — a lower headline figure, but one that spans two separate operations, two anaesthetics, and an extended inter-stage wait of several weeks while cells are expanded in an external laboratory. The comparison is not like-for-like: the cost differential partly reflects the condensed, single-session pathway and the on-site biological processing that STACi requires.

London Cartilage Clinic, at 66 Harley Street, is currently the only centre in the UK offering STACi, operating as an ICRS Teaching Centre of Excellence. The procedure was developed by Professor Paul Lee, who leads the candidacy assessment — the necessary first step for any patient considering whether STACi is appropriate for their specific defect, joint, and biological profile.